Agios Pharma (AGIO) Misses Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Agios Pharma (AGIO) PT Raised to $83 at Oppenheimer on 2Q Report; 'Strong Clinical Update'
August 8, 2017 11:20 AM EDTOppenheimer raised its price target on Agios Pharma (NASDAQ: AGIO) to $83.00 (from $75.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst Leah Cann notes the company delivered second quarter earnings per share results below expectations from higher research & development... More
